CRIS Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2016βFY2025
Curis Inc had $9.4M of revenue in fiscal 2025, down 13.4% on the year before. Over five years, revenue changed β2.7% a year on average.
Last close Β· Oct 23, 2026
$0.39
4.6%Hi! I read Curis Incβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β13.4%
No. Sales fell 13.4% last year.
Does it make a profit?
β80.3%
No. It lost money last year.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
0.0x
One share costs 0.0 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Curis Inc did it, and the next one. Share prices often move a lot on those days.
Next results
November 5, 2026
Thursday Β· in 10 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 14, 2026 | Q2 '26 | After the market closes | 10-Q β |
| May 12, 2026 | Q1 '26 | After the market closes | 8-K β |
| Mar 19, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 6, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 5, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 6, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Mar 28, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 14, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Curis Inc had $9.4M of revenue in fiscal 2025, down 13.4% on the year before. Over five years, revenue changed β2.7% a year on average. Its operating margin was β60.5%, up 347.8Β pts: of every 100 in sales, about β60 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Curis Inc lost $7.6M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Curis Inc has $5.1M more cash than debt.
Cash, debt and the ratios that show how comfortably Curis Inc can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $116M | $85.6M | $56.3M | $20.0M | $5.1M |
| Debt incl. finance leases | $0.0M | β | $8.5M | $7.6M | $0.0M |
| Debt / equity | 0.0x | β | 0.4x | β | 0.0x |
| Current ratio | 9.1x | 9.2x | 2.8x | 1.4x | 0.5x |
| Quick ratio | 9.1x | 9.2x | 2.8x | 1.4x | 0.5x |
| Total assets | $162M | $109M | $77.3M | $41.3M | $20.0M |
| Total liabilities | $71.6M | $62.3M | $57.6M | $47.3M | $14.5M |
| Shareholders' equity | $90.7M | $46.6M | $19.7M | β$6.0M | $5.5M |
| Net debt (β = net cash) | β$116M | β | β$47.8M | β$12.4M | β$5.1M |
KIRA Β· Its return on capital was β1,125.5%: every 100 invested in the business earned about β1,126 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Curis Inc passes 3 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 8 | 2 / 8 | 4 / 8 | 3 / 8 | 3 / 8 | 4 / 7 | 2 / 7 | 2 / 8 | 3 / 8 |
| Accruals ratio | β42.6% | β7.5% | β4.5% | β16.4% | β3.5% | β4.3% | β1.7% | β9.6% | β6.5% | 64.1% |
| Altman Z'' | β52.48 | β41.63 | β88.73 | β96.16 | β10.44 | β17.95 | β31.95 | β51.01 | β104.16 | β207.55 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $7.5M | $9.9M | $10.4M | $10.0M | $10.8M | $10.6M | $10.2M | $10.0M | $10.9M | $9.4M |
| Research and development | $18.0M | $45.1M | $24.4M | $22.3M | $23.1M | $34.9M | $43.3M | $39.5M | $38.6M | $28.3M |
| Operating income | β$58.0M | β$49.8M | β$29.3M | β$24.4M | β$24.9M | β$42.1M | β$53.0M | β$48.3M | β$44.5M | β$5.7M |
| Interest expense | $2.8M | $4.0M | $3.9M | $0.8M | $0.0M | $0.0M | β | β | β | β |
| Income tax | β | β | β | β | β | β | β | β | $0.0M | $0.0M |
| Net income | β$60.4M | β$53.3M | β$32.6M | β$32.1M | β$29.9M | β$45.4M | β$56.7M | β$47.4M | β$43.4M | β$7.6M |
| Diluted EPS | β$0.45 | β$1.79 | β$0.98 | β$0.97 | β$0.61 | $0.50 | β$12.14 | β$8.96 | β$6.88 | β$0.58 |
| Diluted shares | 0.13B | 0.03B | 0.03B | 0.03B | 0.05B | 0.09B | 0.00B | 0.01B | 0.01B | 0.01B |
| Cash flow | ||||||||||
| Cash from operations | β$35.8M | β$48.4M | β$30.1M | β$26.2M | β$25.7M | β$37.6M | β$54.3M | β$38.4M | β$39.6M | β$27.2M |
| Capital expenditure | $0.3M | $0.2M | $0.1M | $0.0M | $0.7M | $0.0M | $0.4M | $0.0M | β | β |
| Free cash flow | β$36.1M | β$48.5M | β$30.2M | β$26.2M | β$26.4M | β$37.6M | β$54.8M | β$38.4M | β | β |
| Depreciation and amortization | $0.2M | $0.2M | $0.2M | $0.1M | $0.1M | $0.2M | $0.2M | $0.3M | $0.2M | $0.2M |
| Stock-based compensation | $4.3M | $5.4M | $3.9M | $2.7M | $2.7M | $5.3M | $6.8M | $6.0M | $5.9M | $4.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $44.5M | $60.2M | $24.3M | $20.5M | $168M | $116M | $85.6M | $56.3M | $20.0M | $5.1M |
| Total debt | $19.9M | $47.5M | $42.4M | $0.0M | $0.9M | $0.0M | β | $8.5M | $7.6M | $0.0M |
| Current assets | $48.2M | $64.3M | $28.0M | $25.0M | $173M | $122M | $92.1M | $60.9M | $26.4M | $6.9M |
| Current liabilities | $13.5M | $14.1M | $13.3M | $6.5M | $10.1M | $13.4M | $10.0M | $22.0M | $19.0M | $14.1M |
| Property and equipment, net | $0.4M | $0.4M | $0.3M | $0.2M | $0.7M | $0.5M | $0.7M | $0.4M | $0.2M | $0.1M |
| Goodwill | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M |
| Total assets | $57.8M | $73.8M | $37.4M | $35.1M | $204M | $162M | $109M | $77.3M | $41.3M | $20.0M |
| Total liabilities | $28.5M | $49.8M | $41.9M | $69.0M | $73.7M | $71.6M | $62.3M | $57.6M | $47.3M | $14.5M |
| Preferred stock | β | β | β | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $29.5M | $24.0M | β$4.5M | β$33.9M | $131M | $90.7M | $46.6M | $19.7M | β$6.0M | $5.5M |
| Margins | ||||||||||
| Operating margin | β771.1% | β502.7% | β281.3% | β243.5% | β229.8% | β395.0% | β521.7% | β482.2% | β408.3% | β60.5% |
| EBITDA margin | β768.5% | β500.4% | β279.6% | β242.2% | β228.5% | β393.5% | β519.5% | β479.7% | β406.5% | β58.7% |
| Net margin | β802.6% | β538.7% | β312.4% | β321.3% | β276.0% | β426.7% | β557.7% | β473.0% | β397.8% | β80.3% |
| FCF margin | β480.1% | β490.4% | β289.1% | β262.4% | β243.8% | β353.3% | β538.8% | β383.5% | β | β |
| Returns | ||||||||||
| Return on capital | β950.1% | β349.9% | β169.9% | β | β | β | β | β | β | β1,125.5% |
| Return on capital employed | β131.3% | β83.4% | β121.6% | β85.3% | β12.8% | β28.3% | β53.6% | β87.5% | β200.3% | β97.0% |
| Return on equity | β205.1% | β199.5% | β334.2% | β | β61.8% | β41.0% | β82.6% | β143.2% | β634.7% | β |
| Return on assets | β104.6% | β81.1% | β58.6% | β88.7% | β25.0% | β24.8% | β41.8% | β50.9% | β73.2% | β24.8% |
| Return on tangible equity | β295.1% | β355.2% | β | β | β24.6% | β55.6% | β150.8% | β443.6% | β | β |
| Growth | ||||||||||
| Revenue growth | β | 31.5% | 5.4% | β4.1% | 8.3% | β1.7% | β4.6% | β1.4% | 8.8% | β13.4% |
| EPS growth | β | β | β | β | β | β | β2,528.0% | β | β | β |
| Share count change | β | β77.5% | 11.0% | 0.2% | 46.7% | 88.1% | β94.9% | 13.4% | 19.1% | 108.7% |
| Financial health | ||||||||||
| Debt / equity | 0.7x | 2.0x | β | β | 0.0x | 0.0x | β | 0.4x | β | 0.0x |
| Interest coverage | β20.9x | β12.5x | β7.5x | β30.8x | β | β | β | β | β | β |
| Current ratio | 3.6x | 4.6x | 2.1x | 3.8x | 17.1x | 9.1x | 9.2x | 2.8x | 1.4x | 0.5x |
| Quick ratio | 3.6x | 4.6x | 2.1x | 3.8x | 17.1x | 9.1x | 9.2x | 2.8x | 1.4x | 0.5x |
| Capital allocation | ||||||||||
| Capex / revenue | 4.4% | 1.9% | 0.8% | 0.4% | 6.2% | 0.0% | 4.1% | 0.0% | β | β |
| Stock comp / revenue | 57.5% | 54.1% | 37.8% | 26.6% | 24.9% | 49.6% | 66.4% | 59.9% | 54.3% | 42.6% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 5.0 | 2.0 | 4.0 | 3.0 | 3.0 | 4.0 | 2.0 | 2.0 | 3.0 |
| Altman Z'' | β52.5 | β41.6 | β88.7 | β96.2 | β10.4 | β17.9 | β32.0 | β51.0 | β104.2 | β207.5 |
| Accruals ratio | β42.6% | β7.5% | β4.5% | β16.4% | β3.5% | β4.3% | β1.7% | β9.6% | β6.5% | 64.1% |
Source: SEC EDGAR XBRL filings (CIK 0001108205). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
